Arcus Biosciences Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Arcus Biosciences stock.
View analyst ratings for Arcus Biosciences or view top-rated stocks.

Wall Street analysts have given Arcus Biosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Arcus Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Arcus Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Arcus Biosciences.

Arcus Biosciences will be holding an earnings conference call on Thursday, August 5th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

Arcus Biosciences, Inc. (NYSE:RCUS) released its quarterly earnings data on Tuesday, May, 4th. The company reported ($1.08) EPS for the quarter, missing the Zacks' consensus estimate of ($0.86) by $0.22. The business earned $9.46 million during the quarter, compared to analyst estimates of $18.80 million. Arcus Biosciences had a negative trailing twelve-month return on equity of 31.34% and a negative net margin of 196.76%.
View Arcus Biosciences' earnings history.

Arcus Biosciences' stock was trading at $16.97 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, RCUS stock has increased by 85.1% and is now trading at $31.41.
View which stocks have been most impacted by COVID-19.

8 brokers have issued 12 month target prices for Arcus Biosciences' shares. Their forecasts range from $28.40 to $70.00. On average, they expect Arcus Biosciences' stock price to reach $50.55 in the next twelve months. This suggests a possible upside of 60.9% from the stock's current price.
View analysts' price targets for Arcus Biosciences or view top-rated stocks among Wall Street analysts.

4 employees have rated Arcus Biosciences CEO Terry Rosen, Ph.D. on Glassdoor.com. Terry Rosen, Ph.D. has an approval rating of 100% among Arcus Biosciences' employees. This puts Terry Rosen, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Arcus Biosciences include Mirati Therapeutics (MRTX), Biohaven Pharmaceutical (BHVN), United Therapeutics (UTHR), BridgeBio Pharma (BBIO), HUTCHMED (HCM), Arrowhead Pharmaceuticals (ARWR), Evotec (EVTCY), Perrigo (PRGO), Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), I-Mab (IMAB), Sarepta Therapeutics (SRPT), Ultragenyx Pharmaceutical (RARE), Ionis Pharmaceuticals (IONS) and Apellis Pharmaceuticals (APLS).
View all of RCUS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcus Biosciences investors own include Horizon Therapeutics Public (HZNP), BioDelivery Sciences International (BDSI), Pfizer (PFE), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), CRISPR Therapeutics (CRSP), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Agile Therapeutics (AGRX) and Advanced Micro Devices (AMD).

(RCUS) raised $99 million in an IPO on Thursday, March 15th 2018. The company issued 7,100,000 shares at a price of $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO.

Arcus Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "RCUS."

Arcus Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Alliancebernstein L.P. (0.07%), Zurcher Kantonalbank Zurich Cantonalbank (0.02%) and Tarbox Family Office Inc. (0.00%). Company insiders that own Arcus Biosciences stock include Carolyn C Tang, Gilead Sciences Inc, Jennifer Jarrett, Juan C Jaen, Kathryn E Falberg, Robert C Goeltz II, Terry J Rosen, William Grossman and Yasunori Kaneko.
View institutional ownership trends for Arcus Biosciences.

RCUS stock was purchased by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Tarbox Family Office Inc., and Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have bought Arcus Biosciences stock in the last two years include Gilead Sciences Inc, Kathryn E Falberg, Robert C Goeltz II, William Grossman, and Yasunori Kaneko.
View insider buying and selling activity for Arcus Biosciences or or view top insider-buying stocks.

Shares of RCUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RCUS stock can currently be purchased for approximately $31.41.

Arcus Biosciences has a market capitalization of $2.23 billion and generates $77.52 million in revenue each year. The company earns $-122,860,000.00 in net income (profit) each year or ($2.24) on an earnings per share basis.

Arcus Biosciences employs 236 workers across the globe.

The official website for Arcus Biosciences is www.arcusbio.com.

Arcus Biosciences is headquartered at 3928 Point Eden Way, Hayward CA, 94545.

Arcus Biosciences' mailing address is 3928 Point Eden Way, Hayward CA, 94545. The company can be reached via phone at 510-694-6200 or via email at [email protected]